论文部分内容阅读
目的:对11例肾移植术后患者合并应用CsA和依那普利,分別在合并用药前、合用7天后、停药7天后测定患者的血压、血清肌酐、尿素氮、CsA血药浓度。结果:患者合并用药前后的血清肌酐、尿素氮、CsA血浓度经统计学t检验无显著性差异,合并用药后血压较合并用前有显著下降(收缩压降低P<0.01,舒张压降低P<0.05)。结论:①依那普利与CsA合并用药时能对抗CsA相关性高血压,②对患者的肾功能无不良影响且具有一定的CsA肾毒性的防护作用,③基本不影响CsA的体内代谢。
OBJECTIVE: To determine the blood pressure, serum creatinine, blood urea nitrogen, and serum CsA concentration in CsA and enalapril combined with CsA and enalapril in 11 patients after renal transplantation. Results: There was no significant difference in serum creatinine, blood urea nitrogen and serum CsA before and after the combination therapy in the patients. The blood pressure after the combination therapy was significantly lower than that before the combination (systolic blood pressure decreased, diastolic blood pressure decreased, P < 0.05). Conclusion: Enalapril combined with CsA can antagonize CsA-related hypertension, and has no adverse effect on renal function and certain CsA nephrotoxicity protective effect, and does not affect the in vivo metabolism of CsA.